Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 307 of the 314 references it cites were found in a registry or an index; 93 of the 282 sources its claims cite were checked for support.

The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines

Open access

Abstract

BSG/UK-PBC treatment and management guidelines for PBC.

Overview

CoChat Summary

TL;DR

This BSG/UK-PBC guideline provides 40 recommendations for diagnosing and managing primary biliary cholangitis, centred on UDCA 13–15 mg/kg/day first-line, OCA for inadequate response or intolerance, and life-long risk-stratified follow-up. It also covers symptom control, complications of advanced liver disease, special populations, and audit standards.

Key findings

  • UDCA is recommended for all patients with PBC at 13–15 mg/kg/day, usually life-long if tolerated; a combined analysis of three trials (548 patients) showed a one-third reduction in risk of death or transplant for moderate to severe PBC, with survival free of liver transplantation improved in medium- and high-risk bilirubin groups and histological stage IV.
  • In patients with inadequate response to UDCA or UDCA intolerance, defined as ALP >1.67 × ULN and/or elevated bilirubin <2 × ULN, OCA addition is recommended for consideration; in the phase III trial, biochemical response was 10% with placebo vs 47% with 10 mg OCA and 46% with 5–10 mg titrated OCA, and mean ALP decrease was 39% and 33% vs 5%, respectively.
  • Risk stratification after 1 year of UDCA should use biochemical response indices; high-risk patients are those with ALP >1.67 × ULN and/or elevated bilirubin <2 × ULN, while low-risk patients are those without cirrhosis with ALP <1.67 × ULN and normal bilirubin.
  • Symptom burden is common and does not correlate with disease stage: pruritus affects approximately 80% of patients at some time, fatigue is reported by over 50% and severe in 20%, osteoporosis affects 20–44%, and approximately one-third of patients with advanced disease develop oesophageal varices over a median of 5.6 years.

Methods

  • This is a clinical practice guideline developed as a consensus document by the British Society of Gastroenterology Liver Section and UK-PBC, with a broad Guidelines Development Group including gastroenterologists, hepatologists, transplant physicians, liver pathologists, and patient representatives.
  • Development used a systematic review of publications identified via PubMed, Medline, and Cochrane database searches completed in June 2017, in line with the AGREE II instrument; recommendations use the GRADE system (Strong/Weak; quality High/Moderate/Low/Very low).
  • The guideline provides 40 recommendations and service standards/audit recommendations, covering diagnosis, drug therapy, symptom management, advanced liver disease, transplantation, pregnancy, overlap syndromes, familial screening, and patient support.

Limitations

  • The paper states that there is no consensus on the optimal non-invasive strategy to stage and monitor disease progression, and insufficient evidence to recommend one risk score over another on the basis of head-to-head data.
  • The paper states that OCA survival benefit has not yet been demonstrated, longer-term efficacy and generalisability need confirmation, and more experience is needed in patients with advanced liver disease; the pivotal trial included patients with cirrhosis but no patients with decompensation.
  • The paper states that evidence for UDCA in pregnancy is limited, off-label therapies such as budesonide and fibrates are not recommended pending phase III trials, and many recommendations are graded Weak or based on Low/Very low quality evidence.
  • Evident from the text: several recommendations rely on expert opinion or limited case-series data, and patients with PBC were not well represented in some cited studies, such as the Baveno VI varices studies.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1136/gutjnl-2017-315259

Cites

307 of 307 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 The BSG/UK-PBC consensus care pathway for patients with primary biliary cholangitis (PBC). While care needs always to be personalised to the patient, there are consensus pathways that are important for patients with PBC, which encompass the important ‘pillars’ of care that are believed to provide optimal management of disease and its complications.
Figure 1 The BSG/UK-PBC consensus care pathway for patients with primary biliary cholangitis (PBC). While care needs always to be personalised to the patient, there are consensus pathways that are important for patients with PBC, which encompass the important ‘pillars’ of care that are believed to provide optimal management of disease and its complications.CC BY · PubMed Central
Figure 2 The histopathology of PBC classical staging systems for PBC divide the histological injury of PBC into four stages: florid duct lesions and portal inflammation without interface activity (stage 1), interface hepatitis, ductular proliferation and periportal fibrosis (stage 2), bridging necrosis or bridging fibrosis (stage 3), and cirrhosis (stage 4).93 These systems are easy to apply and are quite reproducible. However, their practical utility is limited because of the uneven distribution of diagnostic histological lesions of PBC and different disease stages co-existing at any time.93 Furthermore, they incorporate features such as inflammation, which are more appropriately regarded as a manifestation of disease activity (histological ‘grade’) rather than disease progression (histological ‘stage’). A more recent scoring system described by Nakanuma and colleagues sums up individual scores for fibrosis, bile duct loss and severity of chronic cholestasis based on copper-associated protein deposition to assess disease stage and provides a separate system for grading necroinflammatory activity based on cholangitic and hepatitic features.100 Similar to the classical staging systems, the Nakanuma staging system correlates well with clinical and laboratory features. Subsequent studies have suggested that the Nakanuma system is more useful than previously described staging systems in predicting adverse outcomes in patients with PBC101 102 and may also be helpful in predicting treatment responses.79 Another recently described histological scoring system for PBC based on prognostically significant lesions (ie, fibrosis, bile duct loss and lymphocytic interface hepatitis) showed better interobserver agreement and correlation with biochemical abnormalities than traditional scoring systems, but predictive value for adverse outcomes could not be assessed.103 Problems with sampling variability apply to all of the histological staging systems that have been described for patients with PBC, which limits the utility of liver biopsy to assess disease severity in routine clinical practice, but they may still have a role in the context of clinical trials where liver biopsies have been used for risk stratification and as a surrogate marker of treatment outcomes. (A) Early PBC is characterised mainly by portal lesions and mild necroinflammatory changes in the acini. Portal tracts may show cholangiocentric granulomatous inflammation composed of lymphocytes, occasionally numerous plasmacytes, and polymorphs including eosinophils. Lymphoid follicles with germinal centres may form. The lymphoid inflammatory infiltrate extends to the biliary epithelium (cholangitis) (arrow), disrupting the basement membrane sometimes leading to bile duct destruction (florid duct lesion). Granulomas, ranging from small collections of histiocytes to easily discerned non-caseating epithelioid granulomas, may be present in portal tracts near damaged bile ducts and less often in the acini. In the progressive lesion of PBC, lymphocytic interface hepatitis may predominate blurring the portal tract boundary and extending into the acinus (arrowheads). Ductular proliferation at the portal-parenchymal interface may be prominent with associated stromal oedema and neutrophilic inflammation. Parenchymal necroinflammatory activity and hepatocellular injury are usually mild. Small and large cell change and hepatocellular regeneration may be seen (H&E, x20). (B) Keratin 7 immunostaining highlights loss of bile ducts (arrowhead indicates a keratin 7-positive bile duct epithelial remnant) leading to chronic cholestasis with features of feathery degeneration, Mallory-Denk bodies, copper-associated protein deposition in periportal/periseptal hepatocytes (cholate stasis), cholestatic rosettes and biliary metaplasia of hepatocytes (arrow) (keratin 7 immunostain, DAB chromagen, x10). (C) Loss of canals of Hering in acinar zone 1 (arrowheads) detected by keratin 19 immunostaining has recently been proposed as an early feature of PBC in the absence of the classic destructive biliary lesions.104 Focal intraepithelial inflammation (cholangitis) is noted in the K19-positive interlobular bile duct (arrow) (keratin 19 immunostain, DAB chromagen, x20).
Figure 2 The histopathology of PBC classical staging systems for PBC divide the histological injury of PBC into four stages: florid duct lesions and portal inflammation without interface activity (stage 1), interface hepatitis, ductular proliferation and periportal fibrosis (stage 2), bridging necrosis or bridging fibrosis (stage 3), and cirrhosis (stage 4).93 These systems are easy to apply and are quite reproducible. However, their practical utility is limited because of the uneven distribution of diagnostic histological lesions of PBC and different disease stages co-existing at any time.93 Furthermore, they incorporate features such as inflammation, which are more appropriately regarded as a manifestation of disease activity (histological ‘grade’) rather than disease progression (histological ‘stage’). A more recent scoring system described by Nakanuma and colleagues sums up individual scores for fibrosis, bile duct loss and severity of chronic cholestasis based on copper-associated protein deposition to assess disease stage and provides a separate system for grading necroinflammatory activity based on cholangitic and hepatitic features.100 Similar to the classical staging systems, the Nakanuma staging system correlates well with clinical and laboratory features. Subsequent studies have suggested that the Nakanuma system is more useful than previously described staging systems in predicting adverse outcomes in patients with PBC101 102 and may also be helpful in predicting treatment responses.79 Another recently described histological scoring system for PBC based on prognostically significant lesions (ie, fibrosis, bile duct loss and lymphocytic interface hepatitis) showed better interobserver agreement and correlation with biochemical abnormalities than traditional scoring systems, but predictive value for adverse outcomes could not be assessed.103 Problems with sampling variability apply to all of the histological staging systems that have been described for patients with PBC, which limits the utility of liver biopsy to assess disease severity in routine clinical practice, but they may still have a role in the context of clinical trials where liver biopsies have been used for risk stratification and as a surrogate marker of treatment outcomes. (A) Early PBC is characterised mainly by portal lesions and mild necroinflammatory changes in the acini. Portal tracts may show cholangiocentric granulomatous inflammation composed of lymphocytes, occasionally numerous plasmacytes, and polymorphs including eosinophils. Lymphoid follicles with germinal centres may form. The lymphoid inflammatory infiltrate extends to the biliary epithelium (cholangitis) (arrow), disrupting the basement membrane sometimes leading to bile duct destruction (florid duct lesion). Granulomas, ranging from small collections of histiocytes to easily discerned non-caseating epithelioid granulomas, may be present in portal tracts near damaged bile ducts and less often in the acini. In the progressive lesion of PBC, lymphocytic interface hepatitis may predominate blurring the portal tract boundary and extending into the acinus (arrowheads). Ductular proliferation at the portal-parenchymal interface may be prominent with associated stromal oedema and neutrophilic inflammation. Parenchymal necroinflammatory activity and hepatocellular injury are usually mild. Small and large cell change and hepatocellular regeneration may be seen (H&E, x20). (B) Keratin 7 immunostaining highlights loss of bile ducts (arrowhead indicates a keratin 7-positive bile duct epithelial remnant) leading to chronic cholestasis with features of feathery degeneration, Mallory-Denk bodies, copper-associated protein deposition in periportal/periseptal hepatocytes (cholate stasis), cholestatic rosettes and biliary metaplasia of hepatocytes (arrow) (keratin 7 immunostain, DAB chromagen, x10). (C) Loss of canals of Hering in acinar zone 1 (arrowheads) detected by keratin 19 immunostaining has recently been proposed as an early feature of PBC in the absence of the classic destructive biliary lesions.104 Focal intraepithelial inflammation (cholangitis) is noted in the K19-positive interlobular bile duct (arrow) (keratin 19 immunostain, DAB chromagen, x20).CC BY · PubMed Central

Verification

Claims the paper makes

58 Valid · 6 Not valid · 89 Not checked · 33 Own results and interpretations

70 more claims · 19 with their cited sources checked

Create a free account to see all 186 claims and to verify the 31 references still open.

See all claims — free account
  • It may state two separate claims as one. 80
  • Probably not a substantial claim. 44

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 314 references

Research works printed but not linked: 4

  1. Roeb, 2014, [Hepatocellular carcinoma - current aspects of screening, surveillance and therapeutic strategies (revised EASL-EORTC recommendations)], Zentralbl Chir, 139, 175
  2. 10.1016/j.jhep.2015.05.022 · DOI · Paper page
  3. 10.1016/S0140-6736(96)04410-8 · DOI · Paper page
  4. 10.1002/hep.1840150518 · DOI · Paper page

Cited by

See all 362

Metadata

Authors
Hirschfield, G. M., Dyson, J. K., Alexander, G. J. M., Chapman, M. H., Collier, J., Hübscher, S., Patanwala, I., Pereira, S. P., Thain, C., Thorburn, D., Tiniakos, D., Walmsley, M., Webster, G., & Jones, D. E. J.
Affiliations
  • University Hospitals Birmingham NHS Foundation Trust (GB)
  • Newcastle upon Tyne Hospitals NHS Foundation Trust (GB)
  • Royal Free London NHS Foundation Trust (GB)
  • University College Hospital (GB)
  • University of Oxford (GB)
  • University of Liverpool (GB)
  • PBC Foundation (GB)
  • Newcastle University (GB)
  • PSC Support (GB)
Corresponding author
Hirschfield, Gideon M
Venue
Gut
Publisher
BMJ
Published
2018-03-28
Volume
67
Issue
9
Pages
1568-1594
ISSN
  • 0017-5749 (ISSN-L)
  • 1468-3288
OpenAlex
W2794998501
Cited by
362
References
314
Citations by year
2026: 44 · 2025: 49 · 2024: 50 · 2023: 49 · 2022: 46 · 2021: 49 · 2020: 35 · 2019: 36 · 2018: 4
FWCI
17.64
Type
journal article
Language
en
Open access
Locations
  • Gut (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • UCL Discovery (University College London) (submittedVersion)
  • HighWire Press Open Archive (submittedVersion)
  • University of Birmingham Research Portal (University of Birmingham) (submittedVersion, cc-by)
  • University of Birmingham Research Portal (University of Birmingham) (submittedVersion, other-oa)
  • Newcastle University ePrints (Newcastle Univesity) (cc-by)
Funders
  • University Hospitals Birmingham NHS Foundation Trust
  • National Institute for Health and Care Research (NF-SI-0513-10091)
  • University of Birmingham
  • Medical Research Council (MR/L001489/1)
  • Birmingham Biomedical Research Centre
Topics
  • Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
  • Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
  • Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
Keywords
primary biliary cirrhosis, autoimmune liver disease, ursodeoxycholic acid, obeticholic acid, second-line therapy, risk stratification, treatment response, antimitochondrial antibodies, cholestasis, symptom burden, disease progression, patient follow-up
MeSH terms
Alanine Transaminase, Alkaline Phosphatase, Autoantibodies, Bilirubin, Chenodeoxycholic Acid, Cholagogues and Choleretics, Cholangitis, Gastroenterology, United Kingdom, Humans, Liver Cirrhosis, Biliary, Mitochondria, Predictive Value of Tests, Risk Factors, Sensitivity and Specificity, Societies, Medical, Ursodeoxycholic Acid, Biomarkers, Treatment Outcome, Disease Progression, Risk Assessment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines. https://app.cochat.ai/papers/10.1136/gutjnl-2017-315259
The paper
Hirschfield, G. M., Dyson, J. K., Alexander, G. J. M., Chapman, M. H., Collier, J., Hübscher, S., Patanwala, I., Pereira, S. P., Thain, C., Thorburn, D., Tiniakos, D., Walmsley, M., Webster, G., & Jones, D. E. J. (2018). The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines. Gut. https://doi.org/10.1136/gutjnl-2017-315259

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.